Perspective Therapeutics
Yahoo Finance • 11 days ago
Perspective Therapeutics Progresses Dose Finding for [212Pb]VMT01 in Combination with Nivolumab in its Ongoing Phase 1/2a Study of MC1R-Positive Metastatic Melanoma
Perspective Therapeutics, Inc. First patient dosed with [212Pb]VMT01 3.0 mCi in combination with nivolumab [212Pb]VMT01 3.0 mCi single agent dose Cohort re-opened SEATTLE, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc.... Full story
Yahoo Finance • 23 days ago
Perspective Therapeutics Appoints Maya Martinez-Davis to Board of Directors
SEATTLE, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today annou... Full story
Yahoo Finance • last month
Perspective Therapeutics to Participate in Upcoming September Conferences
SEATTLE, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announ... Full story
Yahoo Finance • last month
PERSPECTIVE THERAPEUTICS INC (NYSEARCA:CATX) Surpasses Q2 2025 Revenue Estimates with Narrower Loss
PERSPECTIVE THERAPEUTICS INC (NYSEARCA:CATX [https://www.chartmill.com/stock/quote/CATX/profile]) reported its second-quarter 2025 financial results, delivering revenue that significantly surpassed analyst expectations while posting a narr... Full story
Yahoo Finance • last month
Perspective Therapeutics GAAP EPS of -$0.29 beats by $0.01, revenue of $0.29M beats by $0.12M
* Perspective Therapeutics press release [https://seekingalpha.com/pr/20199058-perspective-therapeutics-provides-recent-business-highlights-and-reports-2q-2025-results] (NYSE:CATX [https://seekingalpha.com/symbol/CATX]): Q2 GAAP EPS of -... Full story
Yahoo Finance • last month
Here are the major earnings before the open Wednesday
Major earnings expected before the bell on Wednesday include: * Tencent Holdings Limited (OTCPK:TCEHY [https://seekingalpha.com/symbol/TCEHY]) * Stratasys Ltd. (SSYS [https://seekingalpha.com/symbol/SSYS]) * Organigram Global (OGI [... Full story
Yahoo Finance • 2 months ago
Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ESMO Congress 2025
SEATTLE, July 24, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announc... Full story
Yahoo Finance • 3 months ago
Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting
SEATTLE, June 21, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (Perspective or the Company) (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, announced two pr... Full story
Yahoo Finance • 4 months ago
Perspective Therapeutics, Inc. (CATX): Analysts See 460% Upside Potential
We recently published an article titled 13 Best Multibagger Stocks to Invest in Now. Perspective Therapeutics, Inc. (NYSE:CATX) was one of the stocks that was covered in that article. Wall Street analysts believe CATX has a 460% upside pot... Full story
Yahoo Finance • 2 years ago
Perspective Therapeutics’ VMT-α-NET Protocols Presented at the North American Neuroendocrine Tumor Society (NANETS) 2023 Symposium
SEATTLE, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced that two upcoming investigator-initiated trials (IIT) were presented at the North American... Full story
Yahoo Finance • 2 years ago
Perspective Announces Presentation of Positive Early Clinical Data for VMT-α-NET at the 36th Annual Congress of the European Association of Nuclear Medicine
Ten patients received therapy, with an initial response seen in 7 out of 9 evaluable patients to date.Responses observed in both peptide receptor radionuclide therapy-naïve and peptide receptor radionuclide therapy-refractory disease. SEA... Full story
Yahoo Finance • 2 years ago
Perspective Therapeutics to Present Clinical and Preclinical Data at the 36th Annual Congress of the European Association of Nuclear Medicine
RICHLAND, WASH. & CORALVILLE, IOWA, Aug. 28, 2023 (GLOBE NEWSWIRE) -- – Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced that it will present new clinical and preclinical data for 21... Full story
Yahoo Finance • 2 years ago
Perspective Therapeutics’ Cesium-131 Featured at the American Brachytherapy Society’s Annual Conference
RICHLAND, WASHINGTON & CORALVILLE, IOWA, June 27, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a precision oncology company developing alpha-particle therapies and comple... Full story
Yahoo Finance • 2 years ago
Perspective Therapeutics Initiates Phase 1/2a Clinical Trials for Two Targeted Alpha Therapy Oncology Product Candidates
VMT-α-NET for neuroendocrine cancers and VMT01 for melanoma are both entering therapeutic trials under IND at leading US institutions. First melanoma patient screened and imaged with [203Pb]VMT01 to determine eligibility for [212Pb]VMT01... Full story
Yahoo Finance • 2 years ago
Perspective Therapeutics’ Cesium-131 to be Featured in Presentations at the 2023 American Brachytherapy Society’s Annual Meeting
RICHLAND, Wash & CORALVILLE, IOWA, June 16, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and... Full story
